Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 11 (Search time: 0.002 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17
Sommeijer, D.
;
Karapetis, C.
;
Zalcberg, J.
;
Tu, D.
;
Jonker, D.
;
Simes, J.
;
Tebbutt, N.
;
Yip, D.
;
Price, T.
;
O'Callaghan, C.
2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.
Siu, L.
;
Shapiro, J.
;
Jonker, D.
;
Karapetis, C.
;
Zalcberg, J.
;
Simes, J.
;
Couture, F.
;
Moore, M.
;
Price, T.
;
Siddiqui, J.
;
Nott, L.
;
Charpentier, D.
;
Liauw, W.
;
Sawyer, M.
;
Jefford, M.
;
Magoski, N.
;
Haydon, A.
;
Walters, I.
;
Ringash, J.
;
Tu, D.
;
et al.
2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
Price, T.
;
Bruhn, M.
;
Lee, C.
;
Hardingham, J.
;
Townsend, A.
;
Mann, K.
;
Simes, J.
;
Weickhardt, A.
;
Wrin, J.
;
Wilson, K.
;
Gebski, V.
;
Van Hazel, G.
;
Robinson, B.
;
Cunningham, D.
;
Tebbutt, N.
2013
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy
Padman, S.
;
Padbury, R.
;
Beeke, C.
;
Karapetis, C.
;
Bishnoi, S.
;
Townsend, A.
;
Maddern, G.
;
Price, T.
2014
Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia
Hocking, C.
;
Broadbridge, V.
;
Karapetis, C.
;
Beeke, C.
;
Padbury, R.
;
Maddern, G.
;
Roder, D.
;
Price, T.
2012
Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
Khattak, M.
;
Townsend, A.
;
Beeke, C.
;
Karapetis, C.
;
Luke, C.
;
Padbury, R.
;
Maddern, G.
;
Roder, D.
;
Price, T.
2013
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17
Vickers, M.
;
Karapetis, C.
;
Tu, D.
;
O'Callaghan, C.
;
Price, T.
;
Tebbutt, N.
;
van Hazel, G.
;
Shapiro, J.
;
Pavlakis, N.
;
Gibbs, P.
;
Blondal, J.
;
Lee, U.
;
Meharchand, J.
;
Burkes, R.
;
Rubin, S.
;
Simes, J.
;
Zalcberg, J.
;
Moore, M.
;
Zhu, L.
;
Jonker, D.
2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Peeters, M.
;
Price, T.
;
Cervantes, A.
;
Sobrero, A.
;
Ducreux, M.
;
Hotko, Y.
;
Andre, T.
;
Chan, E.
;
Lordick, F.
;
Punt, C.
;
Strickland, A.
;
Wilson, G.
;
Ciuleanu, T.
;
Roman, L.
;
Van Cutsem, E.
;
Tzekova, V.
;
Collins, S.
;
Oliner, K.
;
Rong, A.
;
Gansert, J.
2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study
Tebbutt, N.
;
Wilson, K.
;
Gebski, V.
;
Cummins, M.
;
Zannino, D.
;
van Hazel, G.
;
Robinson, B.
;
Broad, A.
;
Ganju, V.
;
Ackland, S.
;
Forgeson, G.
;
Cunningham, D.
;
Saunders, M.
;
Stockler, M.
;
Chua, Y.
;
Zalcberg, J.
;
Simes, R.
;
Price, T.
2012
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancer
Weickhardt, A.
;
Price, T.
;
Chong, G.
;
Gebski, V.
;
Pavlakis, N.
;
Johns, T.
;
Azad, A.
;
Skrinos, E.
;
Fluck, K.
;
Dobrovic, A.
;
Salemi, R.
;
Scott, A.
;
Mariadason, J.
;
Tebbutt, N.
Discover
Author
6
Karapetis, C.
5
Tebbutt, N.
4
Simes, J.
4
Zalcberg, J.
3
Beeke, C.
3
Gebski, V.
3
Jonker, D.
3
Maddern, G.
3
Padbury, R.
3
Townsend, A.
.
next >
Subject
11
Female
11
Humans
11
Male
10
Adult
10
Middle Aged
8
Aged, 80 and over
8
Antineoplastic Combined Chemother...
7
Treatment Outcome
6
Antibodies, Monoclonal, Humanized
5
Disease-Free Survival
.
next >
Date issued
2
2015
2
2014
3
2013
2
2012
2
2010